Callio Therapeutics
Headquartered in Seattle and Singapore, Callio Therapeutics is focused on realising the promise of multi-payload antibody-drug conjugates to transform cancer patient outcomes. The company is developing next-generation, multi-payload antibody-drug conjugates (ADCs) that feature differentiated payload and linker technologies that enable targeted delivery of multi agents to tumor cells to maximize therapeutic benefit. Callio Therapeutics’ lead […]
Callio Therapeutics Read More »